Drug intelligence / Profile preview

AVI-101

Development stage: Preclinical
Lead developer: AbVision
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**AVI-101** is a preclinical **monoclonal antibody** candidate being developed by **AbVision** for **cancer**. Publicly available pipeline information identifies the program as an oncology antibody asset, but does not disclose a specific molecular target, epitope, or mechanism beyond its modality and therapeutic area. Based on the currently available company pipeline disclosure, AVI-101 should be regarded as an undisclosed-target antineoplastic antibody program in preclinical development.

Other names: AVI-101-AbVision-monoclonal antibody-cancerAVI101-AbVision-monoclonal antibody-cancerAVI 101-AbVision-monoclonal antibody-cancer

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on AVI-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVI-101.

Explore the full profile